Cargando…
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019089/ https://www.ncbi.nlm.nih.gov/pubmed/34101785 http://dx.doi.org/10.14283/jpad.2021.12 |
_version_ | 1783674310457556992 |
---|---|
author | Berkness, Tyler Carrillo, M. C. Sperling, R. Petersen, R. Aisen, P. Flournoy, C. Snyder, H. Raman, R. Grill, J. D. |
author_facet | Berkness, Tyler Carrillo, M. C. Sperling, R. Petersen, R. Aisen, P. Flournoy, C. Snyder, H. Raman, R. Grill, J. D. |
author_sort | Berkness, Tyler |
collection | PubMed |
description | BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigators. DESIGN: The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a novel multidisciplinary clinical trial training program funded by the National Institute on Aging and the Alzheimer’s Association with two educational tracks. The Professionals track includes individuals who fill a broad variety of roles including clinicians, study coordinators, psychometricians, and other study professionals who wish to further their knowledge and advance their careers in ADRD trials. The Fellowship track includes current and future principal investigators and focuses on the design, conduct and analysis of ADRD clinical trials. SETTING: The 2020 inaugural iteration of IMPACT-AD was held via Zoom. PARTICIPANTS: Thirty-five trainees (15 Fellowship track; 20 Professionals track) were selected from 104 applications (34% acceptance rate). Most (n=25, 71%) identified as female. Fifteen (43%) were of a non-white race; six (18%) were of Hispanic ethnicity; eight (23%) indicated they were the first person in their family to attend college. MEASUREMENTS: Participants completed daily evaluations as well as pre- and post-course assessments of learning. RESULTS: Across topic areas, >90% of trainees evaluated their change in knowledge based on the lectures as “very much” or “somewhat increased.” The mean proportion correct responses in pre- and post-course assessments increased from 55% to 75% for the Professionals track and from 54% to 78% for the Fellowship track. CONCLUSIONS: IMPACT-AD successfully launched a new training opportunity amid a global pandemic that preliminarily achieved the goals of attracting a diverse cohort and providing meaningful training. The course is funded through 2025. |
format | Online Article Text |
id | pubmed-8019089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-80190892021-04-06 The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program Berkness, Tyler Carrillo, M. C. Sperling, R. Petersen, R. Aisen, P. Flournoy, C. Snyder, H. Raman, R. Grill, J. D. J Prev Alzheimers Dis Original Research BACKGROUND: Alzheimer’s Disease and Related Dementias (ADRD) clinical trials require multidisciplinary expertise in medicine, biostatistics, trial design, biomarkers, ethics, and informatics. OBJECTIVES: To provide focused interactive training in ADRD clinical trials to a diverse cadre of investigators. DESIGN: The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a novel multidisciplinary clinical trial training program funded by the National Institute on Aging and the Alzheimer’s Association with two educational tracks. The Professionals track includes individuals who fill a broad variety of roles including clinicians, study coordinators, psychometricians, and other study professionals who wish to further their knowledge and advance their careers in ADRD trials. The Fellowship track includes current and future principal investigators and focuses on the design, conduct and analysis of ADRD clinical trials. SETTING: The 2020 inaugural iteration of IMPACT-AD was held via Zoom. PARTICIPANTS: Thirty-five trainees (15 Fellowship track; 20 Professionals track) were selected from 104 applications (34% acceptance rate). Most (n=25, 71%) identified as female. Fifteen (43%) were of a non-white race; six (18%) were of Hispanic ethnicity; eight (23%) indicated they were the first person in their family to attend college. MEASUREMENTS: Participants completed daily evaluations as well as pre- and post-course assessments of learning. RESULTS: Across topic areas, >90% of trainees evaluated their change in knowledge based on the lectures as “very much” or “somewhat increased.” The mean proportion correct responses in pre- and post-course assessments increased from 55% to 75% for the Professionals track and from 54% to 78% for the Fellowship track. CONCLUSIONS: IMPACT-AD successfully launched a new training opportunity amid a global pandemic that preliminarily achieved the goals of attracting a diverse cohort and providing meaningful training. The course is funded through 2025. Springer International Publishing 2021-04-02 2021 /pmc/articles/PMC8019089/ /pubmed/34101785 http://dx.doi.org/10.14283/jpad.2021.12 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
spellingShingle | Original Research Berkness, Tyler Carrillo, M. C. Sperling, R. Petersen, R. Aisen, P. Flournoy, C. Snyder, H. Raman, R. Grill, J. D. The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title_full | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title_fullStr | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title_full_unstemmed | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title_short | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program |
title_sort | institute on methods and protocols for advancement of clinical trials in adrd (impact-ad): a novel clinical trials training program |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019089/ https://www.ncbi.nlm.nih.gov/pubmed/34101785 http://dx.doi.org/10.14283/jpad.2021.12 |
work_keys_str_mv | AT berknesstyler theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT carrillomc theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT sperlingr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT petersenr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT aisenp theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT flournoyc theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT snyderh theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT ramanr theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT grilljd theinstituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT berknesstyler instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT carrillomc instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT sperlingr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT petersenr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT aisenp instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT flournoyc instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT snyderh instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT ramanr instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram AT grilljd instituteonmethodsandprotocolsforadvancementofclinicaltrialsinadrdimpactadanovelclinicaltrialstrainingprogram |